Amino-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Serum Levels in Females with Different Thyroid Function States

被引:0
|
作者
Hadzovic-Dzuvo, Almira [1 ]
Kucukalic-Selimovic, Elma [2 ]
Nakas-Icindic, Emina
Lepara, Orhan
Valjevac, Amina
Rasic, Senija [3 ]
Al Tawil, Dinan [4 ]
Begic, Amela [2 ]
Sofic, E. [5 ]
机构
[1] Univ Sarajevo, Dept Physiol & Biochem, Fac Med, Inst Physiol & Biochem, Sarajevo 71000, Bosnia & Herceg
[2] Univ Sarajevo, Ctr Clin, Inst Nucl Med, Sarajevo 71000, Bosnia & Herceg
[3] Univ Sarajevo, Ctr Clin, Clin Nephrol, Sarajevo 71000, Bosnia & Herceg
[4] Policlin Internal Med Al Tawil, Sarajevo 71000, Bosnia & Herceg
[5] Univ Sarajevo, Fac Sci, Sarajevo 71000, Bosnia & Herceg
来源
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI | 2011年 / 36卷 / 02期
关键词
amino-terminal pro-brain natriuretic peptide; NT-proBNP; females; hyperthyroidism; hypothyroidism; HORMONE; HYPERTHYROIDISM; FIBROSIS; BNP;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Aim: Cardiovascular changes that accompany thyroid disorders could be stimulus for the release of BNP from heart ventricles. Different factors, including stress environment conditions, have important role in pathogenesis of thyroid disorders and could possibly affect this response. The aim of this study was to assess the relationship between NT-proBNP and thyroid hormones levels in females with different thyroid functional states. Materials and methods: The study included 104 female patients, age 18-55 years, divided into three groups: hyperthyroid, hypothyroid and euthyroid (control). Serum NT-proBNP, FT3, FT4 and TSH levels were determined in all groups, but in hyper- and hypothyroid group before and after the adequate therapy aimed to the regulation of thyroid status. NT-proBNP concentration was determined by Electrochemiluminescent Immunoassay "ECLIA" method on Roche Elecsys 2010 system. Results: Mean serum NT-proBNP level in hyperthyroid group, before the therapy was 99.35 pg/mL and was significantly higher compared to serum NT-proBNP levels in control (65.90 pg/mL) and hypothyroid group (56.82 pg/mL, p<0.05). After therapy, serum NT-proBNP levels significantly decreased in hyperthyroid (53.64 pg/ml, p<0.01) and significantly increased in hypothyroid group (69.95pg/mL, p<0.04). A significant correlation between serum thyroid hormones, TSH and NT-proBNP levels were observed in hyperthyroid patients, but in hypothyroid patients only between NT-proBNP and FT3 levels. Multiple regression analyses demonstrated that FT3 level was independently associated with serum NT-proBNP levels in hyperthyroid group, after normalization of thyroid status. Conclusion: Thyroid hormones possibly effect BNP secretion and therefore affect the serum NT-proBNP level.
引用
收藏
页码:116 / 121
页数:6
相关论文
共 50 条
  • [41] The use of amino-terminal fraction brain natriuretic peptide (NT-proBNP) assays in general practices in Waikato, New Zealand
    Gibbons, Veronique
    Devlin, Gerard
    Speed, John
    Lawrenson, Ross
    NEW ZEALAND MEDICAL JOURNAL, 2007, 120 (1255) : 21 - 29
  • [42] N-terminal pro-brain natriuretic peptide (NT-proBNP) as screening test for early stage heart failure.
    Triepels, RH
    Busscher, S
    van der Burgh, PH
    Vermes, I
    CLINICAL CHEMISTRY, 2003, 49 (06) : A37 - A38
  • [43] Reduction of unnecessary N-terminal pro-brain natriuretic peptide (NT-proBNP) tests: A further lesson in demand management
    Livingston, Mark
    Kalansooriya, Anura
    Hartland, Andrew
    Fryer, Anthony A.
    Gupta, Jayant
    Heald, Adrian H.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2018, 72 (04)
  • [44] N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE (NT-PROBNP) AS A MARKER OF OUTCOME IN ELDERLY CANCER PATIENTS RECEIVING CHEMOTHERAPY
    Chenevier-Gobeaux, C.
    Montheil, V.
    Mir, O.
    Coriat, R.
    Ekindjian, O. G.
    Goldwasser, F.
    ANNALS OF ONCOLOGY, 2010, 21 : 392 - 393
  • [45] Clinical value of the N-terminal pro-brain natriuretic peptide (NT-proBNP) determination in patients with myocardial infarction (MI)
    Pagani, F
    Bonetti, G
    Stefini, F
    Bonini, E
    Giubbini, R
    Cuccia, C
    Panteghini, M
    EUROMEDLAB 2003: PROCEEDINGS OF THE 15TH IFCC-FESCC EUROPEAN CONGRESS OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2003, : 759 - 762
  • [46] N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) and Risk of Hypertension in the Atherosclerosis Risk in Communities (ARIC) Study
    Bower, Julie K.
    Lazo, Mariana
    Matsushita, Kunihiro
    Rubin, Jonathan
    Hoogeveen, Ron C.
    Ballantyne, Christie M.
    Selvin, Elizabeth
    AMERICAN JOURNAL OF HYPERTENSION, 2015, 28 (10) : 1262 - 1266
  • [47] Plasma N-terminal Pro-Brain Natriuretic Peptide (Nt-proBNP) level and prognosis after myocardial infarction in diabetes
    Verges, B.
    Zeller, M.
    Beer, J. -C.
    Cottin, Y.
    DIABETES & METABOLISM, 2008, 34 : S10 - S15
  • [48] Evaluation of Plasma N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Concentrations in Dogs with Mitral Valve Insufficiency
    Takemura, Naoyuki
    Toda, Noriko
    Miyagawa, Yuichi
    Asano, Kazuyuki
    Tejima, Kenji
    Kanno, Nobuyuki
    Arisawa, Kohji
    Kurita, Tohru
    Nunokawa, Kohji
    Hirakawa, Atsushi
    Tanaka, Shigeo
    Hirose, Hisashi
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2009, 71 (07): : 925 - 929
  • [49] Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma
    Palmer, Suetonia C.
    Yandle, Timothy G.
    Nicholls, M. Gary
    Frampton, Christopher M.
    Richards, A. Mark
    EUROPEAN JOURNAL OF HEART FAILURE, 2009, 11 (09) : 832 - 839
  • [50] Amino-terminal pro-brain natriuretic peptide as a prognostic marker in patients with rheumatoid arthritis
    Bożena Targońska-Stępniak
    Maria Majdan
    Clinical Rheumatology, 2011, 30 : 61 - 69